ArticleCase reports in endocrinology2026
Timing of Denosumab Therapy in Relation to Parathyroidectomy in the Setting of Primary Hyperparathyroidism: Case Report.
Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Timing of Denosumab Therapy in Relation to Parathyroidectomy in the Setting of Primary Hyperparathyroidism: Case Report.Case reports in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal timing of denosumab therapy in relation to parathyroid surgery to avoid hypocalcemia and rebound bone resorption is not well described. Herein we report the case of a 62-year-old woman with steroid-induced osteoporosis who received denosumab for several years prior to undergoing parathyroidectomy. She had a history of lupus and required 20-60 mg of daily prednisone. Prior to her presentation at our institution, she was initially treated with alendronate and calcium/vitamin D supplementation. A dual-energy X-ray absorptiometry (DXA) scan 4 years after starting prednisone showed stable osteopenia in the lumbar spine and total hip but osteoporosis in the femoral neck with a significant reduction of bone mineral density (BMD) by 15.4% since baseline. Denosumab was initiated by her local endocrinologist for antiresorptive therapy due to declining bone density while on alendronate. She remained on prednisone for three additional years while on denosumab. 3 years of denosumab therapy resulted in stable bone density. Vitamin D levels were appropriate but elevations in PTH and calcium were noted. What was initially thought to be secondary hyperparathyroidism was at this point consistent with primary hyperparathyroidism (PHPT). A 4-dimensional computed tomography (4D CT) scan of the neck identified a parathyroid adenoma, and she was referred to our institution for parathyroidectomy. The timing of parathyroidectomy in relationship to the next denosumab injection was a concern due to the rebound bone resorption phenomenon and increased risk of vertebral fractures if denosumab is delayed or missed. Conversely, if denosumab is given in the periprocedural period, severe postsurgical hypocalcemia can result if denosumab prevents liberation of calcium from bone. Considering this, parathyroidectomy was performed 6 months after the last denosumab dose, and it was resumed 8 weeks after surgery. 1 month after surgery, calcium was normal, and PTH had recovered to mid-normal range. Her postoperative course was uncomplicated, and she was able to resume denosumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.